24
Participants
Start Date
September 30, 2006
Primary Completion Date
June 30, 2009
Study Completion Date
March 31, 2010
Extended-release nicotinic acid versus placebo
Voluntary men with mixed dyslipidemia and abdominal obesity will receive extended release nicotinic acid. The dose of niaspan will be up-titrated for 3 weeks starting at 500 mg/d in order to reach 2g/d at start of week 4 dose which will be continued until the end of week 8. After a wash-out period of 3 weeks, they will receive placebo for 8 weeks. According to their randomization arm, subjects will receive either in first place placebo followed by extended release nicotinic acid or the opposite.
Centre de Recherche en Nutrition Humaine, Nantes
Collaborators (1)
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
GlaxoSmithKline
INDUSTRY
Centre de Recherche en Nutrition Humaine Rhone-Alpe
OTHER